Overview
- The first book to cover comprehensive analysis of the EU, US and China patent system as applied to Human Embryonic Stem Cell related Inventions
- Comparatively discusses the moral status of human embryo in the EU, US and China
- Observes “stem cell tourism” phenomenon in China and finds inconsistent moral standards between patent law and practical application in China
- Offers the regulatory governance of human embryonic stem cell research in China, setting out a feasible approach to monitoring stem cell research in China
- Draws lessons from EU harmonization of human embryonic stem cell related regulation, and considers the reconciliation of human embryonic stem cell regulation at the international level
- Includes supplementary material: sn.pub/extras
Access this book
Tax calculation will be finalised at checkout
Other ways to access
About this book
The general scope of the book is the patentability and morality of human embryonic stem cell research in US, EU and China. The book observes fraudsters operate unsafe human embryonic stem cell therapies and officialdom turns a blind eye to the immoral human embryonic stem cell research in China. The book highlights that both patent control and federal funding control are inefficient and ineffective way to monitoring human embryonic stem cell research. The book finally proposed an approach for china to regulating human embryonic stem cell research-regulating research itself at the reconciled international regime.
The potential reader includes academics and practitioners dealing with intellectual property, patent law and stem cell inventions. The topic discussed will also be interesting to a broad readership, including experts, regulators, policy makers and medical researchers in both ethical and legal disciplines in the field of embryonicstem cell research.
The potential reader includes academics and practitioners dealing with intellectual property, patent law and stem cell inventions. The topic discussed will also be interesting to a broad readership, including experts, regulators, policy makers and medical researchers in both ethical and legal disciplines in the field of embryonicstem cell research.
Similar content being viewed by others
Keywords
Table of contents (8 chapters)
-
Front Matter
-
Back Matter
Authors and Affiliations
About the author
Li Jiang is currently a lecturer in Kenneth Wang School of Law, Soochow University. Born in China, Li Jiang was educated at Shandong University, China and graduated with a Bachelors degree in Biotechnology. Li Jiang gained her PhD degree at Bangor University Law School in 2014. Jiang’s research looks at the scope of patentability in respect of the application of the moral exclusion to human embryonic stem cell research through a comparative analysis of the diverging interpretations which have emerged in the regulations of US, EU and China. Many pieces of Jiang’s work have been published by leading international journals in Australia and the United States.
Bibliographic Information
Book Title: Regulating Human Embryonic Stem Cell in China
Book Subtitle: A Comparative Study on Human Embryonic Stem Cell’s Patentability and Morality in US and EU
Authors: Li Jiang
DOI: https://doi.org/10.1007/978-981-10-2101-5
Publisher: Springer Singapore
eBook Packages: Law and Criminology, Law and Criminology (R0)
Copyright Information: Springer Science+Business Media Singapore 2016
Hardcover ISBN: 978-981-10-2100-8Published: 11 August 2016
Softcover ISBN: 978-981-10-9528-3Published: 12 June 2018
eBook ISBN: 978-981-10-2101-5Published: 01 August 2016
Edition Number: 1
Number of Pages: XVIII, 200
Number of Illustrations: 2 b/w illustrations
Topics: Medical Law, IT Law, Media Law, Intellectual Property, Bioethics